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INTRODUCTION: Solid tumors are known to have an abnormal vasculature that limits the distribution of
chemotherapy. We have recently shown that tumor vessel modulation by low-dose photodynamic therapy (L-PDT)
could improve the uptake of macromolecular chemotherapeutic agents such as liposomal doxorubicin
(Liporubicin) administered subsequently. However, how this occurs is unknown. Convection, the main mechanism
for drug transport between the intravascular and extravascular spaces, is mostly related to interstitial fluid pressure
(IFP) and tumor blood flow (TBF). Here, we determined the changes of tumor and surrounding lung IFP and TBF
before, during, and after vascular L-PDT. We also evaluated the effect of these changes on the distribution of
Liporubicin administered intravenously (IV) in a lung sarcoma metastasis model. MATERIALS AND METHODS: A
syngeneic methylcholanthrene-induced sarcoma cell line was implanted subpleurally in the lung of Fischer rats.
Tumor/surrounding lung IFP and TBF changes induced by L-PDT were determined using the wick-in-needle
technique and laser Doppler flowmetry, respectively. The spatial distribution of Liporubicin in tumor and lung
tissues following IV drug administration was then assessed in L-PDT–pretreated animals and controls (no L-PDT)
by epifluorescence microscopy. RESULTS: L-PDT significantly decreased tumor but not lung IFP compared to
controls (no L-PDT) without affecting TBF. These conditions were associated with a significant improvement in
Liporubicin distribution in tumor tissues compared to controls (P b .05). DISCUSSION: L-PDT specifically enhanced
convection in blood vessels of tumor but not of normal lung tissue, which was associated with a significant
improvement of Liporubicin distribution in tumors compared to controls.
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The efficacy of drug therapy is partly related to the ability of the
therapeutic agent to reach its target. The delivery of chemotherapeu-
tics to tumors was shown to be influenced by the tumor blood supply,
the drug transport through the vascular wall, and the drug diffusion/
convection through the interstitial space [1,2]. Various methods have
been tested to improve drug distribution, including isolated organ
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modulation [3–5].
Photodynamic therapy was initially designed to destroy tumor cells
and the tumor vasculature. It consists of the administration of a
photosensitizer that, after activation by nonthermal light, produces a
variety of changes at the cellular level in the treated area [6]. Recently,
low-dose photodynamic therapy (L-PDT) was shown to enhance the
extravasation of macromolecular compounds into tumors [7,8]. For
example, vascular L-PDT of sarcoma metastasis in a murine model
resulted in a significant and selective enhancement of liposomal
doxorubicin (Liporubicin; Regulon Inc, Athens, Greece) in tumors.
The enhanced drug penetration in tumors was observed with different
modes of Liporubicin administration (IV and isolated lung
perfusion). Similar results were found in a different murine model
of colon cancer, lung adenocarcinoma, and mesothelioma [7–10].
However, the precise mechanism by which L-PDT improves drug
transport through the tumor vasculature remains unknown.
For macromolecular drugs (b100 nm in diameter), it was recently
demonstrated that convection is the main promoter of drug
extravasation between the intravascular and extravascular spaces
[11]. The latter is dependent on the Starling equation that includes
two main parameters, namely, tumor hydrostatic and oncotic
pressures. A hallmark of malignant cancer is the angiogenic switch
that primarily occurs through vascular endothelial growth factor.
High levels of vascular endothelial growth factor were shown to alter
the tumor vascular organization, to increase vascular permeability and
the interstitial fluid pressure (IFP) thus hindering convection and
drug delivery [1,2,4]. Many methods have been suggested to improve
drug uptake and selectivity in tumors among which is vasculature
“normalization.” The latter was shown to occur with low doses of
antiangiogenic therapy given at appropriate intervals, which caused a
transient decrease in tumor vascular permeability and IFP. This made
the vessels function in a more “normal” way and improved convection
and concomitant drug delivery to tumors [2,4].
In the present study, we hypothesized that L-PDT caused a
transient improvement in the function of tumor vasculature in a
somewhat similar way to “vascular normalization.” In a rodent model
of sarcoma metastasis, we studied the changes in tumor and lung
tissue (IFP) as well as TBF before, during, and up to 1 hour after low-
dose Visudyne (Novartis, Hettlingen, Switzerland)–mediated L-
PDT. In parallel, the uptake of Liporubicin administered IV was
determined by epifluorescent microscopy in tumor and lung tissues.
Material and Methods
Study Design
Thirty-eight Fischer rats (Charles River Laboratories, France)
underwent subpleural sarcoma implantation in their left lower lobe.
This was followed 10 days later by a re-thoracotomy.Tumor L-PDTwas
performed using Visudyne and laser light. This was directly followed by
the administration of Liporubicin, which was allowed to circulate for 1
hour. IFP was measured in tumor and normal lung in 10 and 8 animals,
respectively, before and during 1 hour following L-PDT. In a separate set
of five animals, TBF was measured in tumors before and during 1 hour
following L-PDT. Liporubicin concentration and distribution in tumors
and surrounding lung were assessed by epifluorescence microscopy
performed on samples embedded in a cryogenic gel (OCT; Electron
Microscopy Sciences, Hatfield, PA, USA) in the different treatment
groups (n = 5 per group, total = 10). Finally, five animals were used ascontrols with no L-PDT. In these, all procedures including Visudyne
and Liporubicin were injected, but no light was delivered.
Animals and Housing
Male Fischer rats weighing 250 to 300 g were treated in accordance
with the Animal Welfare Act and the National Institutes of Health
“Guidelines for the Care andUse of Laboratory Animals” and according
to the Local Ethical Committee of the University of Lausanne.
Tumor Cell Line
A syngeneic methylcholanthrene-induced sarcoma (MCA) cell line
was used as previously described [3]. It was cultivated at 37°C with 5%
CO2 in 20 ml of Roswell Park Memorial Institute (RPMI) medium
1640 medium containing glutaril, 10% FBS, and 1% penicillin/
streptomycin (Invitrogen Corporation/Gibco/Life Technologies Ltd,
Paisley, United Kingdom).
Subpleural Tumor Generation in the Left Lower Lung Lobe
This procedure was performed as described previously [3]. Briefly,
animals were anesthetized by pentobarbital sodium (50 mg/kg), and
oro-tracheal intubation was performed using a 16-gauge polyethylene
Angiocath (Becton Dickinson, Sandy, UT). Animals were ventilated
with a mixture of oxygen and isofluran (0.5%-2%, Forene; Abbott,
Zug, Switzerland) using a tidal volume of 10ml/kg and a respiratory rate
of 75 to 90/min. A left-sided minithoracotomy was performed through
the seventh intercostal space, and 0.1 ml of MCA cell solution
containing 5 × 107 viable tumor cells was injected subpleurally into the
left lower lobe using a 27-gauge needle [12]. The thoracotomy was
closed layer by layer, and the endotracheal tube was removed.
L-PDT of Lungs Bearing Sarcoma Metastasis
Treatment was initiated when the tumors had reached a size of
approximately 4 to 6 mm in diameter (approximately 7 days) as
previously described [13]. The animals were anesthetized, and a left-
sided thoracotomy was performed through the fourth intercostal
space. The left lung was freed from its adhesions. A left cervical
incision was performed to cannulate the external jugular vein.
Visudyne was dissolved in NaCl (0.9%) and glucose (5%) and
injected at a dose of 0.0625 mg/kg. After 15 minutes, laser light was
applied to the exposed lower lung at a wavelength of 689 nm by an
optical fiber–based frontal light distributor (Medlight, Ecublens,
Switzerland) coupled to a diode laser (4-W laser diode; Biolitec,
Germany). Noncontact, nonthermal surface irradiation was per-
formed to the tumor and the surrounding normal lung tissue with the
incident laser beam directed perpendicular to the lung surface and
centered on the tumor. The treatment spot had a diameter of 30 mm,
and the treated area was exposed to an irradiance of 35 mW/cm2 and
a light dose of 10 J/cm2 corresponding to a treatment time of
approximately 5 minutes. The irradiances and the light doses were
measured in real-time as previously described [7,12].
IV Administration of Liporubicin
Immediately after laser light delivery, 400 μg of Liporubicin
dissolved in 0.5 ml of 6% Hydroxyethyl Starch (HAES) was injected
through the external jugular vein catheter. The time interval between
Liporubicin administration and harvesting of the left lung
(Liporubicin circulation time) was 60 minutes. Control animals
underwent exactly the same operative procedure (including
Visudyne injection) but had no light therapy (no laser and kept in
the dark) before Liporubicin administration.
Figure 1. (A) Impact of L-PDT on tumor and lung IFP. The chart
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IFP in tumors and lung tissues was determined using the wick-in-
needle technique [14]. Briefly, a custom-made 28-gauge needle with a
200-μm side hole located approximately 2 mm from the needle tip was
coupled to a pressure sensor by a water column in polyethylene tubing
(0.58-mm inner diameter), filled with heparinized water (70 U/ml).
Three nylon sutures (7-0) were threaded through the needle to form the
“wick.” The signal from the pressure sensor was passed through an
amplifier and digitalized (in aMacLab/4e AD InstrumentCoorporation
(Dunedin, New Zealand) converter). Data were collected using a
Personnal Computer (PC) with PowerLab Chart software version 4.2
(ADInstruments Ltd). Before each experiment, the system was
calibrated against a predefined height where the needle was submersed
in a sterile water solution at tumor level (zero reference, heart level of the
animal) and at a predefined elevation. A fresh, sharp needle was then
introduced at the center of the tumor and in the subpleural parenchymal
space of normal lung tissue in the L-PDT irradiation field but away
from the tumor. Fluid communication between the tumor and the
pressure transducer was checked by briefly clamping the tubing, hence
causing a brief compression and decompression of the tube; when fluid
communication was satisfactory, IFP quickly returned to the same value
as before the clamping operation. The values were then allowed to
stabilize and give the mean IFP. For lung IFP measurements, a change
in the pressuremeasured thatmirrored the ventilator suggested an intra-
alveolar or intra-airway location of the needle. In this case, fluid
communication was lost, and the needle was replaced in the lung
parenchyma. Tests for adequate fluid communication were then
repeated. L-PDT could be performed with the needle in place, and real-
time evaluation of IFP could be determined. IFP was measured before,
during, and at 10-minute intervals following L-PDT for up to 1 hour
(time at which Liporubicin had circulated for 60 minutes and that the
animals were killed). Every 10 minutes, fluid communication was
checked by the clamping operation. At the end of the experiment, the
needle was placed in sterile water, and calibration was checked to ensure
no clogging of the needle had occurred.
Laser Doppler Flowmetry
TBF was determined by laser Doppler flowmetry perfusion
measurement using a setup with a Periflux 4001 laser Doppler
flowmeter (Perimed, Stockholm, Sweden) and a custom-built probe
such as previously described [14]. Laser light at a wavelength of 780 nm
was transmitted into the lung from the 42°C heated probe. The probe
was held steady in the desired position by amicromanipulator. TBF was
recorded continuously for 2 to 3 minutes, whereas the calculated
perfusion in arbitrary perfusion units (PU) was monitored graphically.
During recording, care was taken to position the probe such that
respiratory movements did not influence the readings (this was
determined from the graphic representation of measured PU values).
As soon as steady state had been reached (typically in 60-90 seconds),
three individual values were noted from the display. The median of
these three values was used for further data analysis. The TBF
measurement apparatus was calibrated to 250 PU in a “motility
standard” reference solution (Perimed) before the measurements, and
calibration was regularly confirmed. Calibration was stable over time.represents the changes in IFP before (30 minutes before L-PDT),
during, and 1 hour after L-PDT in tumors and normal lung in
sarcoma metastasis to rodent lungs (mean ± SEM; *P b .05
between initial and given time points, time in minutes). (B) Changes
in tumor and lung IFP with only Visudyne and Liporubicin injection
(no L-PDT) for 1 hour are shown.Quantification of Liporubicin Distribution in Tumor and
Lung Tissues
Harvested lungs were embedded in cryogenic embedding medium
(OCT), sectioned, and visualized using an epifluorescence micro-scope to determine doxorubicin signal as previously described [13].
For each lung, a series of four red green blue (RGB) images in the
tumor and in the normal lung was performed using a mercury lamp
coupled to a 580-nm absorbance filter. This allowed visualizing the
distribution of doxorubicin, the basic component of Liporubicin that
is encapsulated in liposomes. Hereafter and throughout the text,
Liporubicin quantification refers to doxorubicin signal quantification
as this is the active component at the cellular level of Liporubicin. To
determine the distribution of Liporubicin in the tumor, a custom-
built macro for ImageJ was used as previously described [13]. Briefly,
the RGB images were created, taking highly intense green images that
corresponded to endothelial cell lining (red pseudocolor) and lower
intense signal (green pseudocolor, Liporubicin). The dilation
function was applied to the red pseudocolor image for sequential
dilations. A new RGB image was recreated, and the overlap between
green and red channels was quantified using the RGB colocalization
function in ImageJ that quantifies the overlapped green and red
pixels. This signal was corrected for initial overlap and background
pixel count on the nondilated image and divided by the number of
vessels per image (cross-checked by conventional histology). The
results represent the presence of Liporubicin pixels as a function of
distance from vessels in the different treatment groups, in other
words, its distribution within tumors.
Statistical Analysis
Liporubicin signal at increasing distances from tumor vessels was
assessed using a Student’s t test in Excel (Microsoft Corporation,
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IFP and TBF changes were compared to initial values using a paired
t test and between time points using a Student’s t test where a
bidirectional hypothesis was applied. Results were considered
significant when P b .05.)
Results
Tumor IFP Changes with L-PDT
Before L-PDT treatment, tumor IFP values were significantly
higher than lung values (4 ± 1.5 mm Hg vs 0 ± 0.25 mm Hg,
respectively; P b .05). To exclude hemodynamic instability caused by
anesthesia, we determined continuous tumor and lung IFP values
during the first 30 minutes following anesthesia induction (Figure 1A,
pre–L-PDT). IFP values remained constant throughout this time
frame. IFP was then measured in a constant way during and up to 1
hour following L-PDT. L-PDT caused a persistent decrease in tumors
but not lung IFP (Figure 1A) that was significantly lower than the
pre–L-PDT values up to 30 minutes following light delivery. Between
30 and 60 minutes following L-PDT, tumor IFP was lower than the
pre–L-PDT values, but this difference was not significant. Interest-
ingly, tumor and lung IFP levels were not affected by Visudyne or
Liporubicin administration in the five control animals when no light
was administered (Figure 1B).
Tumor Laser Doppler Flowmetry with L-PDT
We then determined the effect of L-PDT on TBF by performing
laser Doppler flowmetry. Because of the continuous ventilation, lung
Doppler flowmetry was not possible as the ventilated lung caused many
artifacts. Because the tumor tissue was thicker and more compact, TBF
assessment in tumors was feasible and reproducible. The mean value of
TBF after stabilization was of 493 ± 38 PU. L-PDT caused a brief
decrease in TBF to 352 ± 46 PU in the immediate post–L-PDT period.
The tumor L-PDT values recovered to pre–L-PDT values within 10
minutes following L-PDT. These values remained constant throughout
the 60 minutes of the experiment (Figure 2).igure 2. Laser Doppler flowmetry assessment of TBF before,
uring, and after L-PDT (in arbitrary PU) in sarcoma tumors
enerated on rodent lungs. There is a significant drop in TBF
uring L-PDT that recovers 10 minutes after L-PDT (mean ± SEM;F
d
g
d
*P b .05 between initial and current time points, time in minutes).Liporubicin Assessed by Fluorescence Microscopy
To determine the spatial distribution of Liporubicin in tumors
following IV administration, we quantified Liporubicin signal in
tumor sections by epifluorescence microscopy (Figure 3, A and B).
Liporubicin consists of doxorubicin encapsulated in liposomes.
Doxorubicin has intrinsic fluorescent properties with an emission
signal that can be recorded at an emission of 580 nm when excited by
a mercury lamp. In animals treated with IV alone, doxorubicin signal
was confined to the vascular area at the periphery of the tumor with a
very sparse signal observable in the tumor interstitium. In tumors
pretreated by L-PDT, however, the doxorubicin signal was increased
and more homogenous throughout the tumor interstitium
(Figure 3A). Signal quantification showed that L-PDT significantly
enhanced the penetration depth of doxorubicin from the tumor
vessels compared to IV alone (P b .05). In addition, the total count of
pixels within the first 105 μm around tumor vessels was significantly
higher in the L-PDT compared to the IV-alone group. These date
suggested an enhanced and more homogenous availability of the drug
within the tumors after L-PDT (Figure 3B).
Discussion
Photodynamic therapy was shown to induce a variety of effects
ranging from transient changes in the tumor vasculature to direct
tumor cytotoxic effects. A recent concept where PDT is applied at
low drug/light conditions was shown to specifically affect the tumor
but not normal vasculature [12,13]. These studies have shown that L-
PDT of the tumor vasculature could significantly enhance the
distribution of drugs administered subsequently without affecting its
distribution in normal tissue [7,8]. The precise mechanism of L-PDT
is still unknown as this concept is relatively new. In prostate cancer,
vascular-targeted PDT was shown to enhance effective permeability
of tumor vessels [15]. This was hypothesized to occur through the
contraction of endothelial cells on the basis of in vitro results [15].
The same mechanism has also been suggested in a separate study on
heterotopic colic cancer [8]. This was based on effective permeability
assessments by studying the distribution of increasing fluorescent
bead sizes before and after L-PDT. Interestingly, it is also known that
effective permeability or molecule distribution do not necessarily
correspond to the intrinsic vessel permeability. For example, it was
well demonstrated that solid tumors have wide networks of neovessels
that are very permeable and cause IFP to be high [16]. In addition,
studies on antiangiogenic therapy have demonstrated that limiting
vessel intrinsic permeability could decrease IFP, enhance convection
between the intravascular and extravascular spaces, and enhance drug
distribution or effective permeability of molecules in tumors as long as
the drugs, such as Liporubicin, have a diameter below or equal to 100
nm [4,11]. In this study, we found that L-PDT decreased tumor but
not lung IFP and had no effect on TBF (Figure 4A). This resulted in
an enhancement of Liporubicin distribution in tumors. If we consider
the IFP changes induced by L-PDT and postulate that the constant
TBF, following L-PDT, suggests a stable intravascular hydrostatic
pressure, the application of the Starling equation in our model
predicts that L-PDT enhanced drug convection between the
intravascular and extravascular spaces (Figure 4B). Moreover, because
neovessels are highly permeable, it seems very unlikely that
endothelial cell contraction and tumor vascular permeability increase
could explain the observed decrease of tumor IFP in our model.
Instead, our data seem to suggest that L-PDT decreases tumor vessel
permeability, which reduces tumor IFP while keeping intravascular
BLung 
Tumor 
Tumor 
Lung 
A
Figure 3. (A) Liporubicin fluorescence reconstruction images in tumors after administration of 400 μg of Liporubicin with and without
L-PDT pretreatment (original magnification, ×40). The green pseudocolor represents Liporubicin signaling, and the red pseudocolor
represents tumor blood vessels. L-PDT pretreatment enhanced the distribution of Liporubicin in the tumor interstitium but not in
lung tissues. (B) Liporubicin signaling quantification in the tumor at increasing distances (μm) from the tumor vessels with and
without L-PDT pretreatment is shown.
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(Figure 4B). Further work to determine vessel pore size in L-PDT–
treated vessels and controls by electron microscopy are necessary for
proper validation of this hypothesis. A similar mechanism has been
demonstrated in solid tumors treated with low doses of antiangio-
genic therapy. These studies have shown that the decrease in vessel
permeability decreased IFP and enhanced convection between the
intravascular and extravascular spaces. These changes were named
“vessel normalization” [4–11]. Separate studies showed that the
decrease in vessel permeability enhanced drug distribution for drug
sizes up to 100 nm in diameter [16]. Our results seem to indicate
that L-PDT caused a drop in IFP through a drop in vessel
permeability. However, as in normalization, tumor vessel perme-
ability did not reach that of normal vessels [4–11]. In other words,
L-PDT–treated tumor vessels had more convection and kept a
certain degree of permeability that favored liporubicin extravasation
and distribution.
An important topic for chemotherapy specificity and efficacy is to
specifically accumulate in tumors while leaving normal tissues
unaffected. In the literature, many approaches have been suggested
to obtain a specific drug distribution in tumors. It was well
demonstrated that tumor vessels and normal vessels are different in
their structure and function. For example, the big vessel gaps in
tumors that are absent in normal vessels were the basis of
macromolecule (i.e., liposome) encapsulation of chemotherapy toenhance tumor drug specificity [17]. Here, we find that L-PDT
administered with the drug/light conditions used has a specific effect
on the tumor vasculature while leaving normal vessels unaffected.
Previous studies have already suggested that the mechanism for drug
distribution enhancement by L-PDT is different in normal and
tumor tissues. In normal tissues, it was shown that the light
irradiation conditions required for enhanced drug distribution were
10-fold higher than those necessary in tumor tissues [13,18,19]. In
addition, it was demonstrated that selectins and the immune system
played an important role for drug distribution enhancement in
normal tissue, whereas this was not the case in tumor tissues [18,19].
The different L-PDT drug/light conditions for tumor versus normal
tissue drug enhancement conditions could therefore be explained by
different mechanisms for drug distribution occurring in normal and
tumor tissues. For example, the contraction of endothelial cells and
enhancement of vessel permeability in normal tissue are expected to
improve drug distribution as IFP is low in normal tissues (i.e., the
basis of an inflammatory reaction) but is not expected to affect tumor
drug distribution (IFP is already high). In addition, differences in
microarchitecture of the vasculature between normal and tumor
tissues could explain the difference in sensitivity of the different
vasculatures [20]. For example, low pericyte coverage is a well-known
characteristic of tumor vessels [20]. Normal vessels, on the contrary,
have a preserved architecture with excellent alignment of endothelial
cells and pericytes [20]. Further work on the vessel architecture and
Figure 4. (A) Combination of Figures 1 and 2 shows a favorable drug distribution period ranging frombefore L-PDT to 60minutes after L-PDT.
(B) Schematic representation of the Starling equation parameters in solid tumors before and after L-PDT. In the pre–L-PDT condition, tumor
vascular intrinsic permeability is increased. This causes oncotic pressures to equilibrate between the intravascular and extravascular spaces
(πi: oncotic capillary pressure; πe: oncotic IFP). This also causes the hydrostatic IFP to be high. L-PDT is thought to induce a change in
vascular permeability that decreases IFP and recreates an oncotic gradient between the intravascular and extravascular space between 10
and 60 minutes following L-PDT. According to the Starling equation, convection is increased after L-PDT compared to the initial time point
(light blue arrow line). As a comparison, a normal vessel is also represented with tight endothelial cell junctions that impair
macromolecule extravasation.
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responsible for permeability changes in tumor vessels.
The effect of photodynamic therapy on tumor IFP has been
studied in the past. Interestingly, the drug/light conditions used were
higher than in the present study and aimed to cause tumor
cytostatism. Dolmans and collaborators, for example, had shown in
MCA4 mammary tumors that photodynamic therapy caused a
transient vasospasm that was followed after 4 hours by vessel
permeability increase [21]. This was also the case in melanomas
grown on hamsters where cytostatic photodynamic therapy caused a
two-phase response with an acute permeability of tumor vessels,
followed by a drop in IFP after 24 hours because of vascular shutdown[22]. It thus appears that phototherapy can have multiple and long-
term effects on the tumor vasculature that are not only confined to the
treatment period. This could be of interest in situations of repeated
chemotherapy administration schemes for clinical translation in
patients. In this study, we chose to only study the short-term effect of
L-PDT on IFP and TBF as chemotherapy was administered once,
and its distribution was assessed after 1 hour. It is mandatory to
further determine how L-PDT affects the tumor and normal
vasculatures for longer periods of time and how this affects
subsequent administrations of chemotherapy. In addition, these
observations further underline the need to obtain specific biomarkers
for L-PDT assessment in patients to better optimize treatments.
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remains complex and invasive, could be of interest in superficially
spreading tumors such as mesotheliomas or oligometastatic pleural
disseminations. Indeed, this therapy has limited side effects and an
important effect on drug distribution enhancement. However, optimal
drug/light conditions are mandatory for tumor blood vessel L-PDT to
be successful. Therefore, a better understanding of how photosensiti-
zation modifies the vascular function and refinements of in situ L-PDT
monitoring aremandatory for the translation of this concept in a clinical
setting. Few parameters currently exist to assess the impact of L-PDT on
the vasculature and thus determine the appropriate sequence of
administration of chemotherapy following L-PDT for best therapeutic
results. On the basis of our study, we find two promising factors, IFP
and TBF, that could be translated in the clinics after validation to
monitor the effect of L-PDT on solid tumors. The application of L-
PDT in combination with chemotherapy could thus be performed
using the wick-in-needle technique in vivo with laser Doppler
flowmetry to monitor and confirm the vascular effect of L-PDT.
Therefore, IFP and TBF could represent two potential biomarkers that
could be used for L-PDT translation in the clinics. Other biomarkers
such as circulation angiogenic factors over time and imaging of vessel
permeability by Magnetic Resonnance Imaging (MRI), for example,
should also be exploited. These elements have shown robustness in
clinical trials combining antiangiogenic therapy with chemotherapy in
the aim to optimize the normalization concept. In the L-PDT field, no
studies have so far been performed with this concept. These elements
therefore require validation but could be of interest to translate L-PDT
in the clinics.
In conclusion, Visudyne-mediated L-PDT has the potential to
selectively enhance Liporubicin distribution in tumors in a model of
sarcoma metastasis to the lung by reducing tumor IFP. The
enhancement of convection in tumors by L-PDT is a novel and
attractive concept that opens new perspectives for the management of
superficially spreading tumors.
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